Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.

Cancer Sci · 2021 · PMC8645742 · PMID 34609773

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In patients who had recurrent EGFR‐amplified WHO grade III/IV glioma, central review showed a trend toward lower median PFS in subgroups with positive EGFR or EGFRvIII versus subgroups with negative EGFR or EGFRvIII.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.